E of a novel genotyping assay targeting the reverse transcriptase-encoding regionE of a novel genotyping

E of a novel genotyping assay targeting the reverse transcriptase-encoding region
E of a novel genotyping assay targeting the reverse transcriptase-encoding region only. J Clin Microbiol 2013, 51:1757?761. 96. Lepage P, Van de Perre P, Simonon A, Msellati P, Hitimana DG, Dabis F: Transient seroreversion in children born to human immunodeficiency virus 1-infected mothers. Pediatr Infect Dis J 1992, 11:892?94. 97. Chantry CJ, Cooper ER, Pelton SI, Zorilla C, Hillyer GV, Diaz C: Seroreversion in human immunodeficiency virus-exposed but uninfected infants. Pediatr Infect Dis J 1995, 14:382?87. 98. Gutierrez M, Soriano V, Bravo R, Vallejo A, Gonzalez-Lahoz J: Seroreversion in patients with end-stage HIV infection. Vox Sang 1994, 67:238?39. 99. Roy MJ, Damato JJ, Burke DS: Absence of true seroreversion of HIV-1 antibody in seroreactive individuals. JAMA 1993, 269:2876?879. 100. Jurriaans S, Sankatsing SU, Prins JM, Schuitemaker H, Lange J, van der Kuyl AC, et al: HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS 2004, 18:1607?608. 101. Kassutto S, Johnston MN, Rosenberg ES: Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005, 40:868?73. 102. Hainaut M, Peltier CA, Goetghebuer T, Van der LD, Marissens D, Zissis G, et al: Seroreversion in children infected with HIV type 1 who are treated in the first months of life is not a rare event. Clin Infect Dis 2005, 41:1820?821. 103. Hare CB, Pappalardo BL, Busch MP, Karlsson AC, Phelps BH, Alexander SS, et al: Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006, 42:700?08. 104. Cornelissen M, Jurriaans S, Prins JM, Bakker M, van der Kuyl AC: Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load. AIDS Res Ther 2006, 3:3. 105. Amor A, Toro C, Jimenez V, Simon A, Ramos B, Soriano V: Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. AIDS 2006, 20:1460?462.doi:10.1186/1742-4690-10-93 Cite this article as: van der Kuyl et al.: Translational HIV-1 research: from routine diagnostics to new virology PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28250575 insights in Amsterdam, the Netherlands during 1983-2013. Retrovirology 2013 10:93.
Wu et al. Retrovirology 2013, 10:112 http://www.retrovirology.com/content/10/1/RESEARCHOpen AccessNew insights into inhibition of human immunodeficiency virus type 1 replication through mutant tRNALysChengxiang Wu1,2, Vivek R Nerurkar3 and Yuanan Lu1*AbstractBackground: Host cellular tRNALys3 is exclusively utilized by human immunodeficiency virus type 1 (HIV-1) as a primer for the replication step of reverse transcription (RTion). Consequently, the priming step of HIV-1 RT constitutes a potential target for anti-HIV-1 intervention. Previous studies indicated that a mutant tRNALys3 with 7nucleotide substitutions in the 3 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28854080 terminus resulted in aberrant HIV-1 RTion from the trans-activation response region (TAR) and inhibition of HIV-1 replication. However, the mutant tRNALys3 also directed HIV-1 RTion from the normal primer-binding site (PBS) with potentially weakened anti-HIV-1 ML240 side effects activity. To achieve improved targeting of HIV-1 RTion at sites not including the PBS, a series of mutant tRNALys3 with extended lengths of mutations containing up to 18 bases complementary to their targeting sites were constructed and characterized.